Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KeyPRP
- Development stage
- Unknown
- Lead developer
- Cervos Medical
- Modality
- Cell Therapies
- Administration
- Injection
01
Overview
KeyPRP is an autologous platelet-rich plasma (PRP) system developed by MD Biologix. It is designed to produce a concentrated suspension of platelets from a patient's own blood. The resulting platelet concentrate is rich in growth factors and cytokines, which are released upon activation to promote tissue repair, angiogenesis, and collagen synthesis. KeyPRP is primarily utilized in regenerative medicine and pain management for musculoskeletal conditions, such as tendon injuries, osteoarthritis, and ligament tears. As an autologous biologic, it minimizes the risk of immune rejection or cross-contamination.
- Brand names
- KeyPRP
- Other names
- Platelet ConcentratePRPPlatelet-Rich Plasma
Beyond the preview
Go deeper on KeyPRP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KeyPRP.